In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Degarelix | Synthetic analog Triptorelin (Trelstar, Decapeptyl) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 329 | 1,338 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 73 (73 in people) | 164 (160 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 148 · 39 active22 more mention it but do not test it | 207 · 44 active104 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Firmagon says: “Treatment of patients with advanced prostate cancer”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Degarelix | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 846222 | 782599171 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
| Adverse eventsWhole body | 5454 | 105105 |
|---|
| Tumor growthKidney and urinary | 665781 | 524624 |
|---|
| Receptor activity and mechanismReproductive and sexual health | 299713 | 7425715 |
|---|
| Sexual functionReproductive and sexual health | 2020 | 761 |
|---|
| Body weightMetabolic and weight | 422 | 17161 |
|---|
| Urinary continence and bladder functionKidney and urinary | 1313 | 55 |
|---|
| PharmacokineticsPharmacology | 817 | 19136 |
|---|
| MortalityWhole body | 44 | 1212 |
|---|
| Immune responseImmune and inflammation | 13454 | 11 |
|---|
| Glycemic controlMetabolic and weight | 211 | 33 |
|---|
| Heart functionCardiovascular | 33 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Degarelix differs from Gonadorelin at 7 positions.
What is different
Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Degarelix | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | −36% Prostate volume change Dose studied: 240 mg initial, then 80 mg monthly12 weeksn = 2442013 | 21 to 97% Nodule volume reduction Dose studied: 3.75 mg every 28 days, four administrationsn = 252007 |
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in days | 3 days Median time to optimal OFS Dose studied: 240 mg on day 1 of cycle 1, then 80 mg on day 1 of cycles 2 through 6n = 512019 | |
| Adverse eventsReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 88% Adverse event rate 18, 24, or 36 monthsn = 3792025 | 71% Adverse events Dose studied: 3.75 mg every 28 days |
−36%
Prostate volume change
Dose studied: 240 mg initial, then 80 mg monthly12 weeksn = 2442013
21 to 97%
Nodule volume reduction
Dose studied: 3.75 mg every 28 days, four administrationsn = 252007
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Degarelix | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| MortalityCancerCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 97% Survival Dose studied: 3.75 mg9 monthsn = 2842003 |
14 days Median time to optimal OFS Dose studied: 3.75 mg on day 1 of every cyclesix 28-day cyclesn = 512019 |
3 days
Median time to optimal OFS
Dose studied: 240 mg on day 1 of cycle 1, then 80 mg on day 1 of cycles 2 through 6n = 512019
14 days
Median time to optimal OFS
Dose studied: 3.75 mg on day 1 of every cyclesix 28-day cyclesn = 512019
88%
Adverse event rate
18, 24, or 36 monthsn = 3792025
71%
Adverse events
Dose studied: 3.75 mg every 28 days3 monthsn = 1252005
| Urinary continence and bladder functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | 61% IPSS response Dose studied: 240/80 mg monthly12 weeksn = 1752012 | No randomized trial result 5 results from other study designs. |
|---|
| Sexual functionReproductive and sexual healthCompared as: difference from placebo, in cohen's d | −0.96 Cohen's d Between-group effect size, Sexual Desire Inventory n = 522022 | No randomized trial result 7 results from other study designs. |
|---|
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in ms | ≤ 10 ms Upper 95% confidence boundary of placebo-corrected ΔΔQTcF · degarelix 2.8 mg, any timepoint Dose studied: 2.8 mg single dosen = 802017 | No randomized trial result 1 result from other study designs. |
|---|
No comparable result
2 randomized-trial results measure it in another way or another unit.
97%
Survival
Dose studied: 3.75 mg9 monthsn = 2842003
61%
IPSS response
Dose studied: 240/80 mg monthly12 weeksn = 1752012
No randomized trial result
5 results from other study designs.
−0.96 Cohen's d
Between-group effect size, Sexual Desire Inventory
n = 522022
No randomized trial result
7 results from other study designs.
≤ 10 ms
Upper 95% confidence boundary of placebo-corrected ΔΔQTcF · degarelix 2.8 mg, any timepoint
Dose studied: 2.8 mg single dosen = 802017
No randomized trial result
1 result from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 148 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radiation Therapy Oncology Group1,538 participantsSept 2009 to 4 Sept 2025
Prostate Cancer
Ferring Pharmaceuticals859 participantsJun 2009 to Mar 2011
Prostate Cancer
Ferring Pharmaceuticals620 participantsFeb 2006 to Oct 2007
Prostate Cancer
22 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024
Breast Cancer
Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)
Prostate Cancer
104 more mention it but do not test it. They only measure it or name it in their text.